Corcept Therapeutics stock (US2176391003): UBS upgrades to Buy as shares surge 11.6%

Corcept Therapeutics shares jumped 11.6% on May 13, 2026, after UBS upgraded the stock to Buy from Neutral and raised its price target to $72 from $44.

Corcept Therapeutics stock surged 11.6% to close at $57.08 USD on Nasdaq on May 13, 2026, following an upgrade to Buy from Neutral by UBS Group, according to MarketScreener as of 05/13/2026. UBS also lifted its price target to $72 from $44, implying about 41% upside from the prior close of $51.16, as reported by GuruFocus as of 05/13/2026. The move reflects optimism around the company's pipeline, including potential approval for Lifyoril in ovarian cancer treatment.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Corcept Therapeutics Incorporated
• Sector/industry: Biotechnology
• Headquarters/country: United States
• Core markets: US endocrinology and oncology
• Key revenue drivers: Korlym sales, pipeline drugs
• Home exchange/listing venue: Nasdaq (CORT)
• Trading currency: USD

Corcept Therapeutics: core business model

Corcept Therapeutics develops drugs that modulate cortisol effects to address severe endocrinologic, metabolic, oncologic, and neuropsychiatric disorders. Its flagship product, Korlym (mifepristone), treats hyperglycemia in adults with endogenous Cushing's syndrome, generating the bulk of revenue. The company advances a pipeline targeting hypercortisolism, solid tumors, ALS, and liver disease, as noted on its IR site.

Main revenue and product drivers for Corcept Therapeutics

Korlym remains the primary revenue driver, with stable sales projections from UBS despite potential generic competition from Teva, which the bank views as overstated. UBS forecasts peak revenue for PROC at $936 million. Upcoming catalysts include Lifyoril approval for ovarian cancer, expected to drive robust uptake and expand revenue streams, per GuruFocus as of 05/13/2026.

Industry trends and competitive position

In the biotech sector focused on cortisol modulation, Corcept holds a niche leadership with Korlym's established market position. The push into oncology via Lifyoril positions it amid rising demand for targeted therapies in ovarian cancer. US investors track such firms for exposure to innovative treatments addressing unmet needs in endocrinology and oncology.

Why Corcept Therapeutics matters for US investors

Listed on Nasdaq, Corcept Therapeutics offers US investors direct access to a biotech advancing cortisol modulators with Korlym's steady cash flow and oncology pipeline potential. Its focus on US-centric trials and markets ties performance to domestic healthcare spending and FDA decisions, key for retail portfolios seeking growth in specialty pharma.

Conclusion

Corcept Therapeutics stock rallied sharply on the UBS upgrade to Buy with a $72 target, highlighting pipeline optimism amid Korlym's stability. Investors monitor FDA progress on Lifyoril and generic risks. The Nasdaq-listed biotech remains a watch for those eyeing cortisol modulation therapies.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.